LONDON – Russia's state-owned investment firm Rusnano has made its first foray into U.S. biotech, joining existing and other new investors in private funding rounds totaling $94.5 million for nanomedicine specialists Selecta Biosciences Inc. and Bind Biosciences Inc.
BioXell SpA grossed CHF57.8 million (US$46.3 million) in an initial public offering on the Swiss Stock Exchange in Zurich to fund ongoing clinical and preclinical development of its portfolio of six drug candidates. (BioWorld International)
RSS